BC
TBIO

Bridgefront Capital’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Bridgefront Capital’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,781
Closed -$254K – 992
2020
Q4 		$254K Buy
+13,781
New +$247K 0.09% 438

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

Bridgefront Capital's TBIO Position: Q1 2021 in Review

Bridgefront Capital sold out of Translate Bio, Inc. Common Stock (TBIO) in Q1 2021, closing a stake of 13,781 shares — an estimated $254K sold.

Bridgefront Capital first reported a position in TBIO in Q4 2020 and held it in 1 quarter. The position peaked at $254K in Q4 2020. 146 funds tracked by Wall St. Rank hold TBIO as of Q1 2021.

  • Bridgefront Capital reported no remaining Translate Bio, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Bridgefront Capital sold 13,781 Translate Bio, Inc. Common Stock shares in Q1 2021, an estimated $254K.
  • Bridgefront Capital first reported a position in Translate Bio, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Bridgefront Capital's Translate Bio, Inc. Common Stock position peaked at $254K in Q4 2020.
  • 146 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q1 2021.

Based on Bridgefront Capital's 13F filing for Q1 2021, filed 17 May 2021.